Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Treasury Shares (2022 - 2026)

Oric Pharmaceuticals filings provide 5 years of Treasury Shares readings, the most recent being $1.1 million for Q1 2026.

  • Quarterly Treasury Shares rose 18.06% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, up 18.06% year-over-year, with the annual reading at $582533.0 for FY2025, 25.95% up from the prior year.
  • Treasury Shares hit $1.1 million in Q1 2026 for Oric Pharmaceuticals, up from $582533.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.1 million in Q1 2026 and bottomed at $191925.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $571258.1, with a median of $485942.0 recorded in 2023.
  • The largest annual shift saw Treasury Shares skyrocketed 123.19% in 2023 before it rose 18.06% in 2026.
  • Oric Pharmaceuticals' Treasury Shares stood at $191925.0 in 2022, then soared by 72.27% to $330631.0 in 2023, then skyrocketed by 39.89% to $462507.0 in 2024, then rose by 25.95% to $582533.0 in 2025, then skyrocketed by 86.46% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Treasury Shares are $1.1 million (Q1 2026), $582533.0 (Q4 2025), and $945945.0 (Q3 2025).